monovalent group c meningococcal vaccine
Trade name: Merck Group C meningococcal vaccine
Vaccineapproved
Approved
Apr 2, 1974
Clinical trial activity
21 trials · 15 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
13
Phase 3
9
Phase 4
7
Earliest trial started Jun 1, 1997 (NCT00314041)
Timeline
Indications
Approved for
Mechanism of action
- Neisseria meningitidisImmunity, active
Neisseria meningitidis immunity, active
Approval history
- approvedApr 2, 1974
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cmc vaccine
- meningococcal c conjugate vaccine
- meningococcal c conjugate vaccine
- meningococcal serogroup c vaccine
- meningococcal type c conjugate vaccine
- menomune-c
- mnc-crm197
- monovalent group c meningococcal vaccine
- serogroup c meningococcal conjugate vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02305446 | Phase 3 | Dec 1, 2014 | Novartis |
| NCT02286895 | Phase 4 | Oct 1, 2014 | Centre for Vaccine Development, Mali, PATH, University of Maryland |
| NCT01717638 | Phase 3 | Nov 1, 2012 | Novartis |
| NCT01434680 | Phase 2 | Sep 1, 2011 | Novartis |
| NCT01367158 | Phase 2 | Jul 1, 2011 | Novartis |
| NCT01339923 | Phase 3 | Apr 1, 2011 | Novartis |
| NCT01027351 | Phase 2 | Jan 1, 2010 | Novartis |
| NCT00866619 | Phase 3 | Mar 27, 2009 | GlaxoSmithKline, PATH |
| NCT00644059 | Phase 3 | Nov 1, 2007 | Novartis |
| NCT00119080 | Phase 4 | Aug 1, 2006 | Centers for Disease Control and Prevention (CDC), Georgia Department of Human Resources, Johns Hopkins University, Maryland Department of Health and Mental Hygiene, University of Pittsburgh |
| NCT00326118 | Phase 3 | Jun 1, 2006 | GlaxoSmithKline |
| NCT00327184 | Phase 3 | Apr 1, 2006 | GlaxoSmithKline |
| NCT00310713 | Phase 4 | Apr 1, 2006 | Novartis |
| NCT00248833 | Phase 1 | Dec 1, 2005 | United States Army |
| NCT00311415 | Phase 3 | Oct 1, 2005 | Novartis |
| NCT00310635 | Phase 4 | Jun 1, 2005 | Novartis |
| NCT00310700 | Phase 4 | May 1, 2005 | Novartis |
| NCT00316654 | Phase 4 | Feb 1, 2005 | Novartis |
| NCT00310674 | Phase 3 | Sep 1, 2004 | Novartis |
| NCT00262015 | Phase 4 | Sep 1, 2003 | Chiron, University of Oxford |
Showing 20 of 21 trials
Page 1 / 2
Organizations
Research & Development (15)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 13 | 13 | 3 | 2004 |
| GlaxoSmithKline | For profit | 3 | 3 | 1 | 2006 |
| PATH | Academic/Hospital | 2 | 1 | 2 | 2009 |
| Centers for Disease Control and Prevention (CDC) | Government | 1 | 1 | 1 | 2006 |
| Centre for Vaccine Development, Mali | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Chiron | For profit | 1 | 1 | 1 | 2003 |
| Georgia Department of Human Resources | Government | 1 | 0 | 1 | 2006 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Maryland Department of Health and Mental Hygiene | Government | 1 | 0 | 1 | 2006 |
| Pfizer | For profit | 1 | 1 | 1 | 1997 |
| United States Army | Government | 1 | 1 | 1 | 2005 |
| University of Maryland | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of Oxford | Academic/Hospital | 1 | 0 | 1 | 2003 |
| University of Pittsburgh | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Wyeth | For profit | 1 | 0 | 1 | 1997 |
15 organizations
Page 1 / 1